⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4619141 | 0.76 | — | — | |
| SCHEMBL23573898 | 0.73 | ALDH1A1 (0.32) | — | |
| Iodide SCHEMBL11806511 | 0.70 | — | — | |
| SCHEMBL6695625 | 0.70 | TRPA1 (0.36) | — | |
| Guanidine SCHEMBL10282688 | 0.70 | — | — | |
| Diallyldisulfide SCHEMBL10282689 | 0.69 | ALDH1A1 (0.65) | — | |
| SCHEMBL1076726 | 0.68 | — | — | |
| SCHEMBL175816 | 0.67 | — | — | |
| SCHEMBL9309534 | 0.67 | — | — | |
| SCHEMBL253402 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| EP-1044967-B1 | 2-Pyridinylguanidine urokinase inhibitors | PFIZER (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6673789-B2 | TREATING INFILTRATION OF IMMUNE CELLS INTO INFLAMMATORY SITES | PFIZER, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030203914-A1 | 2-Pyridinylguanidine urokinase inhibitors | DICKINSON ROGER PETER (GB) | 2003-10-30 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| US-6583162-B1 | 2-pyridinylguanidine urokinase inhibitors | WARNER-LAMBERT COMPANY | 2003-06-24 | — | — | US | disclosed |
| EP-1023268-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LTD (GB) | 2003-05-21 | — | — | EP | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| US-6248738-B1 | ANTIULCER AGENTS, ANGIOGENESIS INHIBITORS, ANTIMETASTASIS AGENTS, ANTITUMOR AGENTS | PFIZER INC. | 2001-06-19 | — | — | US | disclosed |
| EP-1044967-A2 | 2-Pyridinylguanidine urokinase inhibitors | PFIZER INC. (US) | 2000-10-18 | — | — | EP | disclosed |
| EP-1023268-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | Pfizer Limited (GB) | 2000-08-02 | — | — | EP | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
| WO-1999020608-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |